Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q3 2023 · 10-Q
Revenue—
Net Income-$18.49M-$18.49MN/M vs Q3 2022 EPS Diluted-$65.08-$65.08N/M vs Q3 2022 Operating Income-$19,148,000N/M Operating Cash Flowderived-$11,772,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
Free Cash Flowderived-$12,018,000N/M ended Sep 30, 2023 · filed Nov 2, 2023 · 33 d after period end